Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Still a Buy?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) gapped up prior to trading on Tuesday . The stock had previously closed at $21.05, but opened at $21.68. Structure Therapeutics shares last traded at $20.36, with a volume of 67,221 shares traded.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GPCR. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -27.44 and a beta of -2.37. The business’s 50-day moving average is $24.71 and its 200-day moving average is $31.63.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Equities research analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of GPCR. Wellington Management Group LLP raised its holdings in shares of Structure Therapeutics by 2.9% in the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares during the last quarter. FMR LLC raised its stake in shares of Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Structure Therapeutics by 5.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock worth $112,816,000 after acquiring an additional 203,010 shares during the last quarter. Deep Track Capital LP lifted its position in shares of Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after purchasing an additional 1,579,492 shares in the last quarter. Finally, Vestal Point Capital LP grew its stake in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.